BeOne Medicines Q3 revenue rises 34% to $1.9 billion; raises 2026 revenue guidance
BeOne Medicines reported third quarter 2026 total revenue of $1.9 billion, up 34% from the prior year, and GAAP diluted EPS per ADS of $3.28 versus $1.09. The company raised its full-year 2026 total revenue guidance to $6.9 billion to $7.0 billion from $6.6 billion to $6.8 billion, and raised GAAP operating income guidance to $1.2 billion to $1.3 billion.
Key points
- Q3 2026 total revenue $1.9 billion, up 34%; BRUKINSA global revenue $1.4 billion, up 34%
- GAAP diluted EPS per ADS $3.28 vs $1.09; non-GAAP diluted EPS per ADS $4.59 vs $2.65
- FY 2026 total revenue guidance raised to $6.9 billion to $7.0 billion from $6.6 billion to $6.8 billion
- Q3 GAAP gross margin 88% vs 86%, which includes a $22 million non-cash impairment tied to discontinuing POBEVCY promotion
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.